The patent of CD47xPD-L1 bispecific antibody was authorized by US patent office
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. announced that the self-developed bispecific antibody drug (Project No.: IMM2505) targeting both CD47 and PD-L1 was recently authorized by the U.S. Patent Office (application No.: 16/170024). The invention patent of IMM2505 project was first submitted to the U.S. Patent Office, and was authorized by the U.S. patent, consolidating the leading position of ImmuneOnco in CD47 target drug development and bispecific antibody research.
"The patent authorization of IMM2505 project in the United States fully reflects the strong R&D and innovation ability of the company's R&D team, which will greatly improve the market competitiveness of the project and lay a good foundation for developing the global market." "IMM2505 project is a new generation of immunosuppressive agents targeting both CD47 and PD-L1, which is developed based on the" mAb-Trap" technology platform of ImmuneOnco," said Tian Wenzhi, founder and chairman of ImmuneOnco. Previous studies have shown that IMM2505 does not bind to human red blood cells and has strong pharmacodynamics in vivo. We are looking forward to the clinical manifestations of IMM2505. "
IMM2505 is an antibody receptor recombinant protein (mAb-Trap) targeting CD47 and PD-L1 at the same time. It is the first in class in the world. It is a bispecific antibody drug with independent intellectual property rights of ImmuneOnco. It can exert strong anti-tumor effect by activating macrophages and T cells at the same time.
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. was founded in June 2015 and registered in Zhangjiang High Tech Park, Shanghai. The company is mainly committed to the development and research of tumor immunotherapy products, including bispecific antibodies, new recombinant proteins, and TANKTM cell therapy. The common feature of our products is to stimulate and mobilize the immune system of patients to play an anti-tumor effect, and ultimately inhibit the continued growth of tumor cells, reverse a series of malignant symptoms caused by this, so that patients gradually return to a healthy state of the body.
Address: Room 502, 1043 HaLei Road, Pudong New Area, Shanghai, China
Building 7, Lane 908, Ziping Road, Pudong New Area, Shanghai, China
Tel. + 86 21 5835 6573